Skip to main content
S&P 5007,800.38-0.14%DOW51,827.08+0.33%NASDAQ27,233.51-0.48%BTC$82,326.00-1.46%ETH$2,508.87-0.83%GOLD$4,192.70-0.56%OIL$93.67+1.98%
Smart Investors Daily
SID Premium
DN

NASDAQ · DNTH

Dianthus Therapeutics, Inc.

Healthcare · Biotechnology

$82.37

Down-$0.89 (-1.08%)

Updated Oct 12, 2026, 6:52 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.51B
P/E ratio
-12.45
Dividend yield
0.00%
52-week range
$68.85 – $117.88
Volume
738.87K
Avg. volume
657.86K

Price performance · DNTH

DNTH price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

DNTH closed at $82.37 after 20 trading sessions, down 23.51% for the selected period.

Last close
$82.37
Period change
-23.51%
Period low
$82.37
Period high
$107.69
Daily close
View OHLC price history
DNTH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$82.36$85.20$82.13$82.37738.87K
Oct 8, 2026$84.73$84.85$81.06$82.431M
Oct 7, 2026$84.60$86.61$84.13$84.88562.47K
Oct 6, 2026$88.58$88.58$83.185$85.401.35M
Oct 5, 2026$88.44$89.58$86.09$88.04597.42K
Oct 2, 2026$89.05$91.24$87.73$88.21751.39K
Oct 1, 2026$88.40$91.04$87.22$88.32767.03K
Sep 30, 2026$88.19$90.71$87.58$88.051.03M
Sep 29, 2026$87.40$87.69$84.72$87.161.03M
Sep 28, 2026$88.03$89.14$87.04$87.83652.71K
Sep 25, 2026$91.56$92.885$88.335$88.55522.72K
Sep 24, 2026$93.75$94.95$90.36$90.71726.36K
Sep 23, 2026$98.35$98.53$89.78$93.441.19M
Sep 22, 2026$96.84$100.47$96.55$98.351.13M
Sep 21, 2026$95.95$99.67$94.58$96.47933.21K
Sep 18, 2026$101.12$104.5499$96.465$96.812.83M
Sep 17, 2026$104.58$105.845$99.92$101.121.14M
Sep 16, 2026$105.43$107.00$101.60$102.491.04M
Sep 15, 2026$107.85$108.255$104.04$104.77478.96K
Sep 14, 2026$108.36$109.755$106.55$107.69651.47K

Latest DNTH news

The latest Smart Investors Daily articles mentioning DNTH.

Stock researchCompany · Overview

DNTH research

Overview

Company profile and research snapshot.

Company profile

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$67.25
Implied upside
—
Analysts
—
DNTH recent ratings
DateFirmRatingTarget
Sep 11, 2026JP MorganOverweight—
Sep 4, 2026CitigroupBuy—
Aug 6, 2026Truist SecuritiesBuy—
Aug 6, 2026HC Wainwright & Co.Buy—
Aug 5, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to accept

Yahoo · Sep 29, 2026

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Flo

Yahoo · Sep 24, 2026

Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?

Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The capital raise comes after a sharp pullback in Dianthus Therapeutics' share price. The stock fell 4.99% over the last session, 8.83% across the past week and 15.11% over 30 days. However, the 90-day share price return of 2.04% and a year-to-date share price gain of 135.48% suggest that momentum has...

Yahoo · Sep 24, 2026

Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run

Dianthus Therapeutics has delivered a very large 3 year return, which puts a lot of focus on whether the current share price still lines up with what its balance sheet actually supports. With the stock last closing at US$93.44, the open question is how that level stacks up against the book value backing each share. Over the past 3 years the stock has gained roughly 7x. Anyone looking at Dianthus Therapeutics now has to ask whether that kind of move is still grounded in the company’s...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By